CCND1 and prostate carcinoma: A ginsenoside derivative called 1C was shown to inhibit the Wnt pathway in LNCaP—a prostate cancer cell line—by decreasing the levels of β-catenin and TCF4, as well as target genes CCND1 and c-Myc, blocking its proliferation.